Neuphoria Therapeutics, Inc. (NEUP) - רווח נקי למניה (EPS TTM)

Neuphoria Therapeutics Inc. (NEUP) focuses on the global neuropsychiatry market by developing GABA receptor modulators, although the narrow specialization of its pipeline creates binary risks. The change in TTM net income per share demonstrates capital dynamics, where -6.22 reflects the baseline level of the metric. The company's innovative approach is based on precision biology and ion channel modulation for the rapid mitigation of depressive states.
פילוחי מדדים ואנליטיקה של חברת Neuphoria (NEUP)

Net income per share (TTM) expresses the final financial result of Neuphoria Therapeutics Inc. (NEUP) distributed across the total volume of issued capital. This metric measures the actual return of each share, excluding the influence of the overall scale of profit. The efficiency of air delivery for raw materials for Neuphoria Therapeutics Inc. (NEUP) drugs directly impacts operating expenses and the final EPS. By analyzing the trend of the rolling annual EPS, an investor assesses the sustainability of the business model. Positive dynamics confirm the fundamental value of the asset.